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Genomic surveys by methylation-sensitive SNP analysis
identify sequence-dependent allele-specific DNA
methylation
Kristi Kerkel1, Alexandra Spadola2, Eric Yuan1, Jolanta Kosek1, Le Jiang1, Eldad Hod3, Kerry Li1,
Vundavalli V Murty1,3, Nicole Schupf 4, Eric Vilain5,6, Mitzi Morris7, Fatemeh Haghighi7 & Benjamin Tycko1,3
Allele-specific DNA methylation (ASM) is a hallmark of
imprinted genes, but ASM in the larger nonimprinted
fraction of the genome is less well characterized. Using
methylation-sensitive SNP analysis (MSNP), we surveyed
the human genome at 50K and 250K resolution, identifying
ASM as recurrent genotype call conversions from
heterozygosity to homozygosity when genomic DNAs were
predigested with the methylation-sensitive restriction enzyme
HpaII. Using independent assays, we confirmed ASM at 16
SNP-tagged loci distributed across various chromosomes.
At 12 of these loci (75%), the ASM tracked strongly with
the sequence of adjacent SNPs. Further analysis showed
allele-specific mRNA expression at two loci from this
methylation-based screen—the vanin and CYP2A6-CYP2A7
gene clusters—both implicated in traits of medical importance.
This recurrent phenomenon of sequence-dependent ASM
has practical implications for mapping and interpreting
associations of noncoding SNPs and haplotypes with
human phenotypes.
Allele-specific CpG methylation (ASM) is a hallmark of genomic
imprinting, but the characteristics of ASM at nonimprinted loci are
less well understood. DNA methylation tracking as a genetic trait was
found in early studies of human VNTR loci1,2, and a recent study
using genome fractionation uncovered a CpG island with parent of
origin–independent ASM on chromosome 21 (ref. 3). We have
described a microarray-based approach, called MSNP, for genetic
and epigenetic profiling4. Genomic DNA is digested with a non–
methylation-sensitive restriction enzyme with or without a second,
methylation-sensitive, restriction enzyme, such as HpaII. Probes are
synthesized by linker ligation and PCR and hybridized to Affymetrix
SNP arrays. Fragments with internal unmethylated HpaII sites drop
out from the plus-HpaII representations. Thus, by comparing the
results in the minus- and plus-HpaII representations, we can measure
net methylation and also detect ASM, which appears as a conversion
from an AB genotype call to BB or AA.
Here, we report genome-wide surveys for ASM using MSNP at 50K
and 250K resolution. The 50K dataset consisted of single XbaI and
XbaI + HpaII representations from 12 normal tissue samples: periph-
eral blood leukocyte (PBL) DNA from four adults, kidney DNA from
one adult, brain and lung DNA from one adult, DNA from three
placentas (sampled at the fetal surface), and buccal cell DNA from two
adults. On this 50K array, there are 39,100 class 1 SNPs (noninforma-
tive for DNA methylation, because of absence of HpaII sites within the
XbaI fragment), 15,057 class 2 SNPs (informative, because of the
presence of nonpolymorphic HpaII sites) and 4,328 class 3 SNPs (not
reliably informative, because of polymorphic HpaII sites). In assessing
the SNP-tagged loci for ASM, we first eliminated those with weak
signals—below the 10th percentile in the XbaI representations—in
Z5 samples. We next asked for allele call conversions inZ3 samples
in the plus-HpaII representations, producing a list of 74 SNP-tagged
loci. Lastly, we examined the hybridization quality and the selective
reduction in intensity of one of the two alleles for each of these loci
using the perfect match/mismatch (PM/MM) view in dChip5.
We brought forward two of the most convincing candidate loci for
independent validations. SNP rs1042073, in exon 13 of the lacto-
transferrin (LTF) gene, showed AB-AA conversions with HpaII
predigestion in five tissues (PBL, brain, kidney, lung and placenta),
each obtained from a different individual, whereas no AB-BB
conversions were seen (Fig. 1a). These results predicted that the C
allele would be consistently more methylated than the T allele at one or
both of the two HpaII sites in this XbaI fragment. As shown for several
tissues from different individuals (Fig. 1), PCR/RFLP and sequencing
consistently showed a reduced representation of the T allele when the
DNA had been predigested with HpaII, and the same genotype
dependence was seen in an expanded series (Table 1 and Supplemen-
tary Table 1 online). To validate this correlation between ASM and
SNP genotype using a non–PCR-based method, we did DNA blotting
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of genomic DNAs from 21 individuals with the 3 possible rs1042073
genotypes. ASM was readily scored as a doublet band pattern, biallelic
methylation as a single upper band, and biallelic lack of methylation as
a single lower band. As shown in Figure 1d, there was an invariant
relationship between the rs1042073 genotype and the pattern of
methylation, with C-allele homozygotes showing biallelic methylation,
CT heterozygotes showing ASM and TT homozygotes showing
biallelic lack of methylation at this site. Given this notably constant
relationship, we sought artifactual explanations, such as the presence
of a polymorphic HpaII site created by or in linkage disequilibrium
with the index SNP in the same restriction fragment. However,
sequencing excluded this possibility. As ASM is often found at
imprinted loci, we also sought to exclude imprinting as an explana-
tion. We addressed this question by using trios of DNA from maternal
and paternal PBL and placenta (fetal surface) from the offspring.
Among the informative trios, the methylated allele in the LTF exon 13
region was paternal in origin in four but maternal in origin in one,
thus excluding parental imprinting as an explanation for the ASM
(Supplementary Fig. 1 online).
We obtained similar results for a second locus from the 50K survey,
tagged by SNP rs9258170 in the upstream region of the HLA-F gene.
There were AB-AA call conversions with HpaII predigestion in each
of five samples (one kidney, one lung, one brain, one placenta, and
two buccal epithelial cell preparations), and no AB-BB conversions.
As shown by pre-digestion followed by PCR, ASM in the HLA-F
upstream region correlated strongly, although not invariably, with the
local DNA sequence, as scored by SNPs and indels (Table 1 and
Supplementary Fig. 2 online). To ask whether the ASM at the HpaII
sites in this region might reflect more widespread ASM at other CpG
sites, we carried out bisulfite sequencing of a region near the index
SNP. This procedure showed a patch of differential methylation
affecting at least 17 CpG dinucleotides (Supplementary Fig. 2).
We next carried out MSNP using 250K StyI SNP arrays, containing
164,561 class 1 (69%), 57,583 class 2 (24%), and 15,906 class 3 SNPs
(7%). Our 250K survey included six PBL samples, two normal bone
marrow samples, one sample of CD34+Lin– hematopoietic cells, and
three placental samples. We analyzed duplicate technical replicates for
StyI and StyI + HpaII representations, and single determinations for
StyI + MspI (60 microarrays). We asked for call conversions from AB
in StyI to AA or BB in StyI + HpaII in both technical replicates in at
least 2 of the 12 biological samples. To exclude loci with biallelic
hypomethylation, we additionally required that the average StyI +
HpaII intensity be reduced not more than 70% from the average StyI-
only intensity, and that the intensity in the StyI + MspI representation
be at least 40% less than the mean signal with StyI + HpaII. This
procedure produced a list of 58 loci as candidates for ASM. As
expected, this list was depleted in class 1 SNPs (0, 0%) and enriched
in class 2 (31, 53%) and class 3 (27, 47%) SNPs. The opposite analysis,
asking for all class 2 SNPs with persistent AB calls and preserved
intensity of both alleles in the plus-HpaII representations (reduced not
more than 70% from the minus-HpaII intensity) in all heterozygous
samples (requiring at least two of the samples to be heterozygous),
with a signal intensity in the StyI + MspI representation at least 40%
less than the mean signal with StyI + HpaII, yielded 15,454 class 2
SNPs. So within the sensitivity of this method and given the valida-
tions and determination of the true-positive rate below, we estimate
that at least 0.16% of the informative SNP-tagged loci queried by the
array have recurrent ASM in the tissues examined.
As internal controls in this 250K dataset, we found consistent call
conversions at SNPs in three imprinted domains: in a PBL sample at
SNP rs11161318 located 0.5 kb downstream of the 3¢ end of the
MAGEL2 gene, in a bone marrow sample at SNP rs231907 in the
KCNQ1 gene, and in the CD34+ stem cells at SNP rs2107425
upstream of the H19 gene. Monoallelic expression of MAGEL2
mRNA as a result of parental imprinting has been shown previously6,7,
and DNA methylation occurs preferentially on the maternal allele at
multiple sites over this imprinted domain on chromosome 15 (ref. 8),
but ASM has not been previously examined in the MAGEL2
downstream region. We therefore validated the MSNP findings
for this SNP-tagged StyI fragment using pre-digestion followed
by PCR and RFLP. As expected for an imprinted locus, in
which parent-of-origin, not DNA sequence, dictates which allele
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Figure 1 Genotype-dependent ASM in LTF intron 13. (a) Hybridization data from 50K XbaI MSNP. Perfect match (pm) and mismatch (mm) intensities are
shown, and the genotype calls from XbaI and XbaI + HpaII genomic representations are indicated. With addition of HpaII, there is a call conversion from
AB to AA at SNP rs1042073. (b) Predigestion followed by PCR and RFLP assay validating ASM in the XbaI fragment containing SNP rs1042073. Genomic
DNA was digested with XbaI or with XbaI + HpaII, followed by PCR with the indicated primers (arrows). PCR products were digested with BsrDI to score the
RFLP corresponding to SNP rs1042073 (asterisk). In each of these samples and in additional individuals (Table 1), the T allele drops out with HpaII
predigestion, indicating relative hypomethylation. The methylation status of the two HpaII sites between the primers, based on this assay and genomic DNA
(Southern) blotting, is indicated by the circles (methylated, black; ASM, half-black). The image of the ethidium-stained gel is inverted to show the bands as
dark on a light background. (c) Confirmation of ASM by predigestion/PCR/sequencing. The double peak indicating heterozygosity at SNP rs1042073 in the
XbaI-digested samples is nearly a single peak in PCR products from the XbaI + HpaII pre-digested samples. (d) Genotype-dependent ASM downstream of
LTF exon 13 indicated by DNA blotting. In a series of 21 individuals, 10 with rs1042073 genotype CC, 8 with genotype CT and 3 with genotype TT, the
ASM at HpaII site 2, seen as the doublet in the RsaI + HpaII lane, was only observed in tissues from individuals who were heterozygous: individuals
homozygous for the C allele at this SNP showed full methylation of this HpaII site, whereas those homozygous for the T allele lacked methylation at this site.
Overall P ¼ 1.72  108, Fisher’s exact test with null hypothesis of random allelic methylation. B, BsrDI; H, HpaII; M, MspI; R, RsaI; X, XbaI.







































becomes methylated, ASM in the MAGEL2 region did not correlate
with the SNP genotype (Supplementary Fig. 3 online).
We next selected a group of loci reported as having ASM in the
250K data, outside of known imprinted regions, for independent
validations in larger series of individuals. These assays validated ASM
for 14/18 candidate loci examined (true-positive rate 78%). For the
minority of loci that could not be validated, it was evident from PCR
that biallelic hypomethylation, with relatively greater sensitivity of the
SNP array probe sets for one allele, accounted for the false-positive
call conversions. The MSNP data and validations by pre-digestion
followed by PCR and bisulfite sequencing are shown for the CYP2A7
and VNN1 genes in Figures 2 and 3, and examples of validations of
ASM at additional SNP-tagged loci are shown in Supplementary
Figures 3–5 online. In the combined 50K and 250K data, the ASM
correlated strongly with the allele in cis at the index SNP or closely
adjacent informative SNPs for 12/16 (75%) of the validated loci
(Table 1 and Supplementary Table 1).
The known relationship between DNA methylation and gene
expression raised the question of whether this sequence-dependent
ASM might be associated with allele-specific mRNA expression (ASE).
Among four loci that we tested by comparing allelic representation in
cDNA versus genomic DNA, only rare individuals showed ASE of the
LTF and HLA-F genes, whereas many showed strong ASE of the
CYP2A7 and VNN1 genes. Both of these positive examples are in gene
clusters, on chromosome 19 and 6, respectively, which lack classical
upstream CpG islands and show tissue specific expression. Although
our MSNP screen was done using hematopoietic tissues, we directly
assayed ASM and ASE for CYP2A7 in the main expressing organ, the
liver. Comparison of allelic representation in genomic and cDNA PCR
products from the CYP2A7 gene showed strong ASE in 10 of
17 heterozygous human liver samples examined, with relative over-
expression of the same allele in each of these 10 individuals, and
sequencing across multiple intragenic SNPs revealed that the presence
or absence of ASE was strongly dependent on genotype (Fig. 2b
and Supplementary Table 2 online). For VNN1, we confirmed ASM
by predigestion followed by RFLP analysis near the index SNP and
by bisulfite sequencing across a CG-rich region, not dense enough
to qualify as a CpG island, between the index SNP and the first
exon (Fig. 3a,c,d). We found a consistent difference in methylation
patterns between the two alleles, already detectable early in the
Table 1 Sequence dependence of ASM at SNP-tagged loci from the 50K and 250K MSNP screens
dbSNP ID Gene or region Tissue CT (N) Allele C methyl. Allele T methyl. No ASM Binomial test
rs1042073 LTF exon 13 PBL 49 48 0 1 P o 10–8
Placenta 33 31 0 2 P o 10–8
rs6494120 GCNT3 US PBL 48 0 44 4 P o 10–8
rs12873012 POU4F1 DS PBL 45 13 2 30 P ¼ 0.0032
rs6969642 DNAJB6 PBL 30 0 27 3 P o 10–8
rs9366927 FGD2- PIM1 PBL 9 9 0 0 P ¼ 0.002
rs9951893 PHLPP-BCL2 PBL 37 35 0 2 P o 10–8
dbSNP ID Gene Tissue CG (N) Allele C methyl. Allele G methyl. No ASM Binomial test
rs3998799 HLA-F US PBL 15 1 7 7 P ¼ 0.0053; combined
Placenta 6 0 3 3
dbSNP ID Gene Tissue AG (N) Allele A methyl. Allele G methyl. No ASM Binomial test
rs34724660 CYP2 clustera Liver 7 0 7 0 P ¼ 0.0001; combined
PBL 6 0 6 0
rs443731 EFNB1 DS Placenta 14 1 10 3 P ¼ 0.0053
rs943049 PARP4-ATP12A PBL 19 17 0 2 P o 10–5
rs4925109 RAI1 intron 2 PBL 25 0 19 6 P o 10–5
rs6569826 VNN1 US PBL 44 18 0 26 P o 10–5
rs206337 N4BP2L1 intron 1 Placenta 19 8 5 6 n.s.
rs11161318 MAGEL2 DS PBL 9 4 5 0 n.s.
dbSNP ID Gene Tissue AT (N) Allele A methyl. Allele T methyl. No ASM Binomial test
rs3844442 CYP2 clustera PBL 16 0 5 11 P ¼ 0 .001; combined
Liver 15 0 5 10
dbSNP ID Gene Tissue indel (N) Long allele methyl. Short allele methyl. No ASM Binomial test
rs9278271 HLA-F US PBL 8 0 5 3 P ¼ 0.031
rs34039986 CYP2A7 exon 2b PBL 11 10 0 1 P ¼ 0.000031; combined
Liver 9 5 0 4
IDs refer to the SNP used for scoring ASM by HpaII predigestion followed by PCR, sizing gel analysis and/or direct sequencing. Reported are exact P values from two-tail binomial
tests testing the null hypothesis of random allelic methylation. Samples with no ASM were not included in the statistical tests. Index SNPs that create or destroy CpG sites are LTF
rs1042073, VNN1 US rs6569826 and CG018 intron 1 rs206337; the index SNPs do not affect HpaII sites (the enzyme used to score ASM). Methyl., relative hypermethylation of
one allele; combined, pooled data from both tissues; N, number of heterozygotes; n.s., not significant; US, upstream; DS, downstream. See Supplementary Table 1 for additional
features of ASM at 16 validated loci.
aASM in this region of the CYP2Ab-CYP2A7 cluster was haplotype dependent in human livers: samples from individuals heterozygous for SNP rs34724660 all showed ASM, whereas those that
were heterozygous for the nearby SNP rs3844442 but homozygous for rs34724660 did not show ASM.







































hematopoietic lineage (CD34+Lin– cells; Fig. 3d). By comparing
cDNA and genomic PCR products in PBL, we documented a
domain-wide effect, with ASE strongest for VNN1 but also evident
for the other two genes (VNN3 and VNN2) in this cluster (Fig. 3b).
Both of these examples are medically relevant: prior genotype–
phenotype correlations for CYP2A6 (located immediately down-
stream of CYP2A7 and 93% identical in amino acid sequence)
have shown that genes in this cytochrome P450 cluster control
blood nicotine levels and may thereby influence smoking behavior9,
and a recent report described total VNN1 mRNA expression as a
quantitative trait linked to haplotypes, and in turn to HDL
cholesterol levels10. Future methylation-based screens using the
methods developed here will likely uncover additional examples of
sequence-dependent ASM linked to important human traits.
This dependence of ASM on the local DNA sequence in cis is distinct
from other epigenetic phenomena such as imprinting, allelic exclusion,
random monoallelic methylation and expression11–13, and epimutation
(which may be haplotype-dependent in some cases14–17). Mechanisms
leading to sequence-dependent ASM will likely differ among loci:
allele-specific affinity for DNA-binding proteins with downstream
effects on DNA methylation is one obvious possibility and our
findings, and in conjunction with prior data10,18–20, suggests that this
model may apply to the CYP2 and vanin gene clusters. Direct effects
of the DNA sequence on propensity for methylation are another
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Figure 2 Genotype-dependent ASM and ASE in the CYP2 gene cluster. (a) Hybridization data from 250K MSNP showing ASM within the StyI fragment
containing SNP rs3844442 in PBL. See Table 1 for sequence dependence of the ASM at this location in the CYP2 gene cluster, queried by SNPs
rs3844442 and rs34724660. (b) ASE of CYP2A7 mRNA in human livers. Liver DNAs were screened for heterozygosity at SNP rs3815710, and
17 heterozygous samples from different individuals were analyzed for ASE: 10 showed strongly preferential expression of the C allele (Liv2, Liv3 and Liv4,
for example) and 7 showed equal biallelic expression or a slight preferential expression of the A allele (Liv1). As shown in Supplementary Table 2, the
presence or absence of ASE was significantly associated with the genotype at SNP rs3815706 in CYP2A7 intron 3. Sequencing of cloned partial cDNAs
showed that the two common haplotypes in this highly polymorphic gene differ by Z6 amino acids in the region spanning exon 2a to exon 6, suggesting that
the allelic expression bias may have functional consequences (Supplementary Table 2 and data not shown). (c) Confirmation of ASM in the StyI fragment
containing the index SNP in human livers by predigestion/PCR/sequencing. The double peak indicating heterozygosity at SNP rs34724660 becomes nearly a
single peak in PCR products from the HpaII predigested samples. (d) ASM shown by bisulfite sequencing at two positions (gray rectangles) in the CYP2 gene
cluster. The bisulfite clones were assigned to each allele in the index region using SNP rs34724660; the clones from the intragenic CpG island overlapping
exon 2b of the CYP2A7 gene were assigned using SNP rs3815710. Dashes in the bisulfite sequences indicate polymorphic CpG sites present on one allele
and absent on the other.
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Figure 3 Genotype-dependent ASM in the VNN1 gene and allele-specific mRNA expression of all three genes in the vanin cluster. (a) Hybridization data
from 250K MSNP showing ASM in the StyI fragment containing the index SNP rs12205095 in PBL. (b) ASE of three genes in the vanin cluster. Of 47 PBL
samples screened for the rs2294757 SNP in VNN1 exon 1, 24 were heterozygous. Of these, 17 were analyzed for ASE: 16 showed strongly preferential
expression of the A allele (PBL4 and PBL5, for example; sequence chromatograms are in the reverse direction), whereas only one sample showed equal
biallelic expression. In a smaller series of heterozygotes, ASE was also observed for VNN3 and VNN2: of seven heterozygous samples examined for ASE of
VNN2, four showed preferential expression of the A allele (SNP rs1883613), whereas one showed preferential expression of the G allele and two showed
equal biallelic expression; of six heterozygous samples examined for ASE of VNN3, all showed preferential expression of the A allele (SNP rs2294759;
sequence chromatograms are in the reverse direction). (c) Predigestion followed by PCR and RFLP and sequencing validating ASM at a HpaII site in the StyI
fragment containing SNP rs12205095. Genomic DNA was mock-digested or digested with HpaII, followed by PCR with the indicated primers (arrows). PCR
products were digested with TaqI to score the RFLP corresponding to SNP rs6569826 (asterisk). In PBL3 and in additional individuals (Table 1), the G
allele drops out with HpaII predigestion, indicating relative hypomethylation. PBL1 and PBL2 are from homozygotes. (d) ASM in the VNN1 promoter region
shown by bisulfite sequencing. The alleles were distinguished by scoring SNP rs12195735 in each clone. The CD34+Lin– DNA sample and PBL3 and PBL4
are from heterozygotes with the AC genotype. In this region, located 0.5 kb from exon 1, all three samples show a specific pattern of CpG methylation on the
A allele, with a different pattern on the C allele. Dashes indicate polymorphic CpG sites present on one allele and absent on the other.







































possibility21. In practical terms, the phenomenon of sequence-depen-
dent ASM extends the concept of haplotypes to include epigenetic
marks (‘epihaplotypes’) and, as an indicator for the presence of nearby
regulatory polymorphisms that confer the allelic asymmetry, it will
likely be useful for fine mapping and interpreting associations of
noncoding SNPs with complex genetic diseases.
METHODS
MSNP procedure. Genomic DNA from normal human tissues, obtained with
institutional review board approval and anonymous to individual identifiers,
was purified using the DNeasy Blood and Tissue Kit (Qiagen). For both 50K
XbaI and 250K StyI MSNP, we followed the recommended protocol of the SNP
array manufacturer (Affymetrix), but with the addition of an initial HpaII or
MspI digestion for the plus-HpaII and plus-MspI probes. Genomic DNA
(250 ng per representation) was digested with HpaII or MspI in a total volume
of 12 ml (Buffer 1; New England Biolabs) for 3 h, followed by adjustment of the
buffer by addition of 15.8 ml of water and 3.2 ml of 10 Buffer 3 (New England
Biolabs), and a further digestion with StyI for 3 h. StyI linkers were ligated to
the restriction fragments, and PCR was carried out for 30 cycles with linker
primers. We carried out PCR purification using the DNA Amplification Clean-
Up Kit (Clontech), and probe fragmentation (brief exposure to DNase), biotin-
labeling and hybridization as described in the Affymetrix protocol. We
determined intensity values by normalization and model-based expression
(PM-only method) using dChip5. The main determinant of the data quality
is the starting material: the genomic DNA must be high molecular weight. Call
rates were in the range of 89–95% with StyI and StyI + HpaII, with lower call
rates of 76–88%, as predicted, in the StyI + MspI representations, in which
many of the class 2 SNPs dropped out as a result of complete digestion of
internal CCGG sites.
Independent assays for ASM. For the HpaII predigestion followed by PCR,
RFLP and sequencing assays, genomic DNA, 1 mg in 80 ml, was digested with
5 U of HpaII overnight, followed by an additional 5 U of HpaII for 1 h or
incubated in parallel with buffer alone. Of this digested DNA, 25 ng was used
for each PCR (primers in Supplementary Table 3 online). In this predigestion/
PCR assay, we did a control with MspI predigestion, and verified that this
procedure markedly reduce the amount of PCR product obtained under the
same cycling conditions. For bisulfite conversion followed by PCR, cloning and
sequencing, we treated genomic DNA with sodium bisulfite and purified the
converted DNA using the CpGenome DNA modification kit (Chemicon)
according to the protocol of the manufacturer. The bisulfite/PCR primers
and SNP ID numbers for distinguishing the alleles in the HLA-F upstream
region, two positions in the CYP2 gene cluster, and in the promoter region of
the VNN1 gene are listed in Supplementary Table 3. Bisulfite PCR products
were cloned in the pCR 2.1-TOPO vector (Invitrogen), and multiple clones
were sequenced. For methylation-sensitive DNA (Southern) blotting of the LTF
exon 13 region, we digested 3 mg genomic DNA with the indicated restriction
enzymes overnight, followed by electrophoresis on 1% agarose gels, transfer to
Nytran membranes (Schleicher and Schull) and hybridization of the blots with
a 32P-labeled LTF probe. The probe DNA was synthesized by genomic PCR; the
primer sequences are in Supplementary Table 3.
Assays for allele-specific mRNA expression. Reverse transcription PCR was
carried out with cDNAs prepared from total PBL RNA (Protoscript First Strand
cDNA Synthesis Kit, New England Biolabs), using primers specific for VNN1,
VNN2, VNN3 and CYP2A7, designed to span at least one intron and include at
least one exonic SNP with a high minor allele frequency. We avoided SNPs
within the primer sequences and sequences that were identical among family
members, conditions which put strong constraints on primer placement in
these highly polymorphic gene clusters. The controls for these analyses were
genomic PCR products spanning these same SNPs. The primer sequences are
listed in Supplementary Table 3.
Accession codes. NCBI GEO: data have been deposited with accession
code GSE11409.
Note: Supplementary information is available on the Nature Genetics website.
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